Medibank Pvt Ltd (ASX: MPL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medibank Pvt Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medibank Pvt Ltd (ASX: MPL)
Latest News
![A woman's hand draws a stylised 'Top Ten' on a projected surface.](https://www.fool.com.au/wp-content/uploads/2023/09/GettyImages-1206445153-1-400x225.jpg)
Share Gainers
Here are the top 10 ASX 200 shares today
![Stethoscope with a piggy bank and hundred dollar notes.](https://www.fool.com.au/wp-content/uploads/2022/01/health-insurance-2-16.9-400x225.jpg)
Dividend Investing
Hoping to bag the supersized Medibank dividend? You'd better be quick
![Cropped shot of an attractive young female scientist working on her computer in the laboratory.](https://www.fool.com.au/wp-content/uploads/2023/09/health-12-16.9-400x225.jpeg)
Healthcare Shares
With a 6% yield, is this the best ASX healthcare share to buy for dividends?
![A woman stares at the candle on her cake, her birthday has fizzled.](https://www.fool.com.au/wp-content/uploads/2022/05/Birthday-cake-fizzle-16_9-400x225.jpg)
Share Market News
Here are the top 10 ASX 200 shares today
![A women cheers with clenched fists having read some good news on her laptop.](https://www.fool.com.au/wp-content/uploads/2022/03/Some-good-news-16_9-400x225.jpg)
Share Gainers
Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank shares are rising
![Male doctor in a lab coat working at laptop looking serious.](https://www.fool.com.au/wp-content/uploads/2023/09/GettyImages-1207323692-1-400x225.jpg)
Earnings Results
Medibank share price falls after FY24 result disappoints
![a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.](https://www.fool.com.au/wp-content/uploads/2021/12/woman-smile-400x225.jpg)
Share Market News
5 things to watch on the ASX 200 on Thursday
![Five guys in suits wearing brightly coloured masks, they are corporate superheroes.](https://www.fool.com.au/wp-content/uploads/2022/01/Five-superheroes-16_9-400x225.jpg)
Best Shares
Which ASX 200 market sector has been the best performer over 10 years?
![A woman's hand draws a stylised 'Top Ten' on a projected surface.](https://www.fool.com.au/wp-content/uploads/2023/09/GettyImages-1206445153-1-400x225.jpg)
Share Gainers
Here are the top 10 ASX 200 shares today
![Shot of a mature scientists working on a laptop in a lab.](https://www.fool.com.au/wp-content/uploads/2023/09/health-8-16.9-400x225.jpeg)
Dividend Investing
Medibank or NIB shares: Which one should you buy?
![Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.](https://www.fool.com.au/wp-content/uploads/2023/08/dividends-400x225.jpeg)
Dividend Investing
Here's one way to invest $20k to target an average 7% ASX dividend yield
![Shot of a scientist using a computer while conducting research in a laboratory.](https://www.fool.com.au/wp-content/uploads/2023/09/health-11-16.9-400x225.jpeg)
Financial Shares
Can Medibank shares expect a healthy FY25?
Frequently Asked Questions
-
Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.
-
Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2024 | $0.0940 | 100.00% | Final | 26 Sep 2024 |
29 Feb 2024 | $0.0720 | 100.00% | Interim | 20 Mar 2024 |
13 Sep 2023 | $0.0830 | 100.00% | Final | 05 Oct 2023 |
02 Mar 2023 | $0.0630 | 100.00% | Interim | 22 Mar 2023 |
07 Sep 2022 | $0.0730 | 100.00% | Final | 29 Sep 2022 |
04 Mar 2022 | $0.0610 | 100.00% | Interim | 24 Mar 2022 |
08 Sep 2021 | $0.0690 | 100.00% | Final | 30 Sep 2021 |
03 Mar 2021 | $0.0580 | 100.00% | Interim | 25 Mar 2021 |
02 Sep 2020 | $0.0630 | 100.00% | Final | 24 Sep 2020 |
03 Mar 2020 | $0.0570 | 100.00% | Interim | 26 Mar 2020 |
04 Sep 2019 | $0.0740 | 100.00% | Final | 26 Sep 2019 |
05 Mar 2019 | $0.0570 | 100.00% | Interim | 28 Mar 2019 |
05 Sep 2018 | $0.0720 | 100.00% | Final | 27 Sep 2018 |
06 Mar 2018 | $0.0550 | 100.00% | Interim | 28 Mar 2018 |
06 Sep 2017 | $0.0000 | 100.00% | Final | 28 Sep 2017 |
07 Mar 2017 | $0.0525 | 100.00% | Interim | 29 Mar 2017 |
06 Sep 2016 | $0.0600 | 100.00% | Final | 28 Sep 2016 |
04 Mar 2016 | $0.0500 | 100.00% | Interim | 29 Mar 2016 |
MPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Medibank Pvt Ltd
Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.
As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.
Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.
In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.
MPL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Sep 2024 | $3.84 | $0.01 | 0.26% | 8,827,511 | $3.81 | $3.84 | $3.79 |
06 Sep 2024 | $3.83 | $-0.02 | -0.52% | 9,335,669 | $3.84 | $3.87 | $3.80 |
05 Sep 2024 | $3.85 | $-0.05 | -1.28% | 7,837,907 | $3.91 | $3.91 | $3.83 |
04 Sep 2024 | $3.90 | $-0.07 | -1.76% | 10,577,754 | $3.87 | $3.91 | $3.85 |
03 Sep 2024 | $3.97 | $-0.02 | -0.50% | 7,411,825 | $3.98 | $4.01 | $3.96 |
02 Sep 2024 | $3.99 | $0.13 | 3.37% | 8,830,683 | $3.87 | $4.00 | $3.86 |
30 Aug 2024 | $3.86 | $-0.02 | -0.52% | 15,835,516 | $3.89 | $3.91 | $3.86 |
29 Aug 2024 | $3.88 | $0.00 | 0.00% | 7,244,047 | $3.87 | $3.90 | $3.85 |
28 Aug 2024 | $3.88 | $0.06 | 1.57% | 13,597,568 | $3.84 | $3.88 | $3.79 |
27 Aug 2024 | $3.82 | $-0.06 | -1.55% | 9,870,895 | $3.87 | $3.91 | $3.81 |
26 Aug 2024 | $3.88 | $-0.06 | -1.52% | 10,176,728 | $3.95 | $3.98 | $3.86 |
23 Aug 2024 | $3.94 | $0.11 | 2.87% | 16,978,494 | $3.87 | $3.96 | $3.84 |
22 Aug 2024 | $3.83 | $-0.09 | -2.30% | 13,758,693 | $3.99 | $3.99 | $3.80 |
21 Aug 2024 | $3.92 | $-0.03 | -0.76% | 6,069,676 | $3.94 | $3.96 | $3.90 |
20 Aug 2024 | $3.95 | $0.01 | 0.25% | 2,575,573 | $3.96 | $3.96 | $3.93 |
19 Aug 2024 | $3.94 | $0.02 | 0.51% | 4,902,870 | $3.93 | $3.98 | $3.93 |
16 Aug 2024 | $3.92 | $0.02 | 0.51% | 6,267,824 | $3.95 | $3.97 | $3.92 |
15 Aug 2024 | $3.90 | $-0.02 | -0.51% | 3,350,984 | $3.92 | $3.96 | $3.89 |
14 Aug 2024 | $3.92 | $0.03 | 0.77% | 3,400,498 | $3.93 | $3.94 | $3.89 |
13 Aug 2024 | $3.89 | $0.01 | 0.26% | 4,136,841 | $3.89 | $3.91 | $3.86 |
12 Aug 2024 | $3.88 | $0.02 | 0.52% | 3,906,428 | $3.89 | $3.90 | $3.86 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Sep 2024 | David Koczkar | Expiry | 260,942 | $1,041,158 |
As advised by the company. Lapsed,1,839,835 Rights
|
02 Sep 2024 | David Koczkar | Exercise | 457,907 | $1,827,048 |
Conversion of securities. 1,381,928 Rights
|
02 Sep 2024 | David Koczkar | Buy | 457,907 | $1,827,048 |
Conversion of securities.
|
26 Aug 2024 | Jay Weatherill | Buy | 5,100 | $19,915 |
On-market trade.
|
26 Aug 2024 | Kathryn Fagg | Buy | 32,750 | $129,362 |
On-market trade.
|
26 Aug 2024 | Michael (Mike) Wilkins | Buy | 100,000 | $396,000 |
On-market trade.
|
26 Feb 2024 | Linda Nicholls | Buy | 5,400 | $19,710 |
On-market trade.
|
11 Dec 2023 | David Koczkar | Issued | 653,088 | $2,292,338 |
Issue of securities. 2,100,777 Performance Rights
|
24 Oct 2023 | David Koczkar | Transfer | 568,030 | $1,993,785 |
As advised by the company. Transfer of 568,030 Ordinary Shares
|
24 Oct 2023 | David Koczkar | Transfer | 568,030 | $1,993,785 |
As advised by the company. Transfer of 568,030 Ordinary Shares
|
26 Sep 2023 | David Koczkar | Exercise | 240,566 | $832,358 |
Conversion of securities. 1,447,689 Performance Rights
|
26 Sep 2023 | David Koczkar | Issued | 14,875 | $51,467 |
As advised by the company. Ordinary Shares having an equivalent value to the dividends that would have been received during the deferral period if Ordinary Shares were held instead of the Performance Rights granted under the FY22 Deferred STI.
|
26 Sep 2023 | David Koczkar | Buy | 240,566 | $832,358 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael (Mike) John Wilkins | Non-Executive DirectorNon-Executive Chairman | May 2017 |
Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He served as Managing Director and Chief Executive Officer at Insurance Australia Group (November 2007 to November 2015), Managing Director and Chief Executive Officer at Promina Group Limited and Managing Director at Tyndall Australia Limited. He also served as Acting Chief Executive Officer (April 2018 to December 2018), Executive Chairman (April 2018 to June 2018) and a director (September 2016 to February 2020) of AMP Limited. He was previously a director of Maple-Brown Abbott Limited, Alinta Limited, The Geneva Association and the Australian Business and Community Network. He is also a director (since November 2016) of QBE Insurance Group Limited. He is also a director of Scentre Group Limited (since April 2020). He is a member of the Investment and Capital Committee and the People Committee.
|
Mrs Linda Bardo Nicholls | Non-Executive Director | Mar 2014 |
Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is currently a director of Inghams Group Limited (since November 2016). Linda is also Chair of the Board of Melbourne Health and a member of the Museums Victoria Board. Linda's previous directorships include Japara Healthcare Limited as Chair (March 2014 to November 2021), Fairfax Media Limited and Sigma Pharmaceuticals Limited. She is Chair of the Investment and Capital Committee and a member of the Risk Management Committee.
|
Ms Kathryn Joy Fagg | Non-Executive Director | Mar 2022 |
Ms Fagg is currently a director of National Australia Bank Ltd (since December 2019), Djerriwarrh Investments Ltd (since May 2014) and she is the Chair of CSIRO. In the non-forprofit sector, she is Chair of Watertrust Australia Ltd and Breast Cancer Network Australia, a director of The Myer Foundation, the Grattan Institute and the Champions of Change Coalition. Kathryn was a non-executive director of Boral Limited from September 2014 to July 2021 including as Chair from July 2018, a non-executive director of Incitec Pivot Limited from April 2014 to December 2019, and a member of the board of the Reserve Bank of Australia from 2013 to 2018. She is a member of the Audit Committee and the People Committee.
|
Mr David Fagan | Non-Executive Director | Mar 2014 |
Mr Fagan held a range of leadership positions at Clayton Utz culminating in the role of Chief Executive Partner for nine years. In this role, David had responsibility and accountability for leadership and transformation, strategy, finance, stakeholder engagement, and governance, including risk management. During David's tenure as Chief Executive Partner, Clayton Utz entrenched itself as a first class top tier commercial law firm. David also chaired the Medibank Privatisation Committee which operated during 2014 in preparation for the privatisation process. David is a former director and Chair of the Audit Committee of The Global Foundation, a former director of Grocon Funds Management Group, the Hilco Group and UBS Grocon Real Estate Investment Management Australia Pty Limited and a former member of the advisory board of Chase Corporate Advisory. David is currently a director of PayGroup Limited (since November 2017). He is Chair of BDO Group Holdings Limited and a member of the ASIC Corporate Governance Consultative Panel. He is Chair of the Risk Management Committee.
|
Mr David Koczkar | Chief Executive OfficerManaging Director | May 2021 |
Mr Koczkar has more than 25 years of strategy, customer and commercial experience, including previous work in the strategy consulting and financial services industries. Prior to joining Medibank, David was the Group Chief Commercial Officer at Jetstar where he was responsible for the airline group's network management, sales and marketing, customer channels and commercial operations, including as a director of Jetstar Pacific (Vietnam), Jetstar Hong Kong and NewStar (Singapore) JV businesses.
|
Mr Peter Dobie Everingham | Non-Executive Director | Mar 2022 |
Mr Everingham has over 25 years of corporate experience and is highly respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes key roles at companies with a consumer and technology focus. Peter is currently a director of Super Retail Group Limited (since December 2017), the owner of several notable Australian brands including BCF, Macpac, Rebel and Supercheap Auto. He is also a director of WWF Australia. He was previously a director of iCar Asia Limited (July 2017 to May 2022), Managing Director of the international division of Seek Limited (and concurrently Chair of Seek's subsidiary, Zhaopin), a director of ME Bank and IDP Education Ltd, and a senior executive for Yahoo! in Australia and Southeast Asia. He is a member of the the People Committee.
|
Dr Tracey Leigh Batten | Non-Executive Director | Aug 2017 |
Dr Batten has experience in the health services sector, with commercial, business and change leadership skills. Tracey is currently a director of EBOS Group Limited (since July 2021), the National Institute of Water and Atmospheric Research in New Zealand and the New Zealand Accident Compensation Corporation, and a former director of Abano Healthcare Group. Tracey was previously the Chief Executive of the Imperial College Healthcare NHS Trust in the United Kingdom. In that role, Tracey focused on change leadership, in particular improving organisational culture and strengthening patient safety and experience. Tracey also oversaw the implementation of a range of digital initiatives as Chief Executive. Tracey is a former Chief Executive of St Vincent's Health Australia, which runs a group of public hospitals, private hospitals and aged care facilities. She is Chair of the People Committee and a member of the Risk Management Committee.
|
Mr Gerard Dalbosco | Non-Executive Director | May 2021 |
Mr Dalbosco held a number of senior leadership roles as a Partner of EY until September 2020. His recent role was Melbourne Managing Partner where he led a team responsible for EY's go-to-market and client service strategies. Prior to this, Gerard held other roles at EY including Asia Pacific Managing Partner - Markets and Co-Deputy CEO where he led EY's client-serving activities across the Asia Pacific market. He was also Oceania Managing Partner and CEO, and Oceania Managing Partner of Transaction Advisory Services where he was responsible for EY's Transaction Advisory Services business across Oceania. Gerard is currently Chair of Melbourne Archdiocese Catholic Schools. He has previously held roles as a director and Chair of the Finance & Audit Committee of Mercy Health & Aged Care, director and member of the Finance Committee of Berry Street Victoria and director and Co-Deputy Chair of the Committee for Melbourne. He is a member of the Risk Management Committee.
|
Mr Jay Wilson Weatherill | Non-Executive Director | Mar 2024 |
--
|
Ms Mei Ramsay | Group General CounselCompany Secretary | Mar 2011 |
-
|
Mei Ramsay | Group General CounselCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 886,438,939 | 32.19% |
J P Morgan Nominees Australia Pty Limited | 454,621,638 | 16.51% |
Citicorp Nominees Pty Limited | 352,442,059 | 12.80% |
National Nominees Limited | 135,979,370 | 4.94% |
Bnp Paribas Noms Pty Ltd <Drp> | 72,474,536 | 2.63% |
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 27,460,612 | 1.00% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 26,018,991 | 0.94% |
Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 26,018,991 | 0.68% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 6,934,877 | 0.25% |
HSBC Custody Nominees (Australia) Limited (ii) | 6,394,969 | 0.23% |
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 6,036,480 | 0.22% |
Bond Street Custodians Limited <Cockej F01832 A/C> | 4,808,007 | 0.17% |
Netwealth Investments Limited <Wrap Services A/C> | 4,671,507 | 0.17% |
BNP Paribas Noms (Nz) Ltd <Drp> | 4,407,028 | 0.16% |
Ioof Investment Services Limited <Ips Superfund A/C> | 4,291,839 | 0.16% |
Navigator Australia Ltd <Sma Antares Inv Dv Build A/C> | 3,721,738 | 0.14% |
Netwealth Investments Limited <Super Services A/C> | 3,067,565 | 0.11% |
Solium Nominees (Australia) Pty Ltd <Vsa A/C> | 2,522,537 | 0.09% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 2,485,524 | 0.09% |
BNP Paribas Nominees Pty Ltd <Agency Lending Collateral> | 2,279,500 | 0.08% |